New York – Paul Hastings LLP, a leading global law firm, represents Genomma Lab Internacional, S.A.B. de C.V. in a 50-50 joint venture between Genomma Lab and Oravax Medical Inc., a majority-owned subsidiary of Oramed, a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, to develop and commercialize Oravax's oral COVID-19 vaccine candidate in Mexico and potentially throughout Latin America.  To deepen the collaboration, Genomma Lab and Oramed also intend to enter into a US$20 million share swap arrangement.

As mentioned in the Genomma Lab press release, a vaccine in the form of a pill could allow easy access to the most isolated and vulnerable communities in the region quickly and effectively since no cold chain or vaccination centers are required.

Genomma Lab is a leading pharmaceutical and personal care products company in Mexico with an increasing international presence. Genomma Lab develops, sells, and markets a broad range of premium branded products, many of which are leaders in their categories. The company operates in 20 countries in the Americas, selling over 50 brands through more than 300,000 points of sale.

Latin America practice partners Mike Fitzgerald and Arturo Carrillo lead the Paul Hastings team, which also included associate Rigoberto Chavez.

At Paul Hastings, our purpose is clear — to help our clients and people navigate new paths to growth. With a strong presence throughout Asia, Europe, Latin America, and the U.S., Paul Hastings is recognized as one of the world’s most innovative global law firms.